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Mycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of
population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst
clinicians for its diagnosis. Management of a HIV-1-leprosy-coinfected individual in a resource-constrained setting is challenging.
Some of these challenges include diﬃculties in establishing a diagnosis of leprosy; the high pill burden of cotreatment with both
antileprosy and antiretroviral drugs (ARVs); medications’ side eﬀects; drug interactions; scarcity of drug choices for both diseases.
This challenge is more profound when managing a patient who requires second-line antiretroviral therapy (ART). We present an
adult male patient coinfected with HIV and leprosy, who failed ﬁrst-line antiretroviral therapy (ART) and required second-line
treatment. Due to limited choices in antileprosy drugs available, the patient received monthly rifampicin and daily lopinavir-
/ritonavir-based antileprosy and ART regimens, respectively. Six months into his cotreatment, he seemed to have adequate
virological control. This case report highlights the challenges of managing such a patient.
1.Introduction
It is a well-established fact that in TB/HIV coinfected pa-
tients, each disease contributes to the progression of the
other.ActiveTBinHIV-1-infectedpatientsisassociatedwith
increasedimmunodeﬁciencyandmortality[1–4].Ithasbeen
speculated that, as with TB, HIV infection may exacerbate
leprosy lesions and/or lead to increased susceptibility to
leprosy. However, there is no good evidence to support
this speculation. Indeed, many studies have found that in
coinfected patients, each disease progresses independently
[5–8].
Treatment of an HIV-1-leprosy coinfected patient re-
quires a potent combination of ARVs as well as antileprosy
agents. The ART must be taken with strict adherence to
achieve maximal suppression of viral replication. This in
turn limits the risk of developing drug resistance [9, 10].
Achieving high adherence levels in coinfected patients may
be challenging due to the high pill burden.
We report the case of a patient coinfected with HIV-1
and leprosy who developed virological failure to ﬁrst-line
ART. He was subsequently switched to second-line ART. Six
months later, antileprosy chemotherapy was initiated.
2.CaseReport
A 66-year-old male was seen in a USAID, Academic Model
Providing Access to Healthcare (AMPATH) Partnership
clinic in western Kenya, complaining of general body itch-
iness and skin patches on the chest for 3 months prior to
contact. He had tested HIV positive three months prior to
enrollment at the clinic. He complained of poor appetite and
hadlost3kg.Hedidnotreportanyallergiestofoodordrugs,
didnotsmoke,butreportedthathetakesalcohol(localbrew)
2-3 times/week.
Onphysicalexamination,hewasinfairgeneralcondition
withaBPof100/60mmHg,pulserateof92beatsperminute,
temperature 36.1◦C, and arterial oxygen saturation of 93%2 Case Reports in Medicine
while breathing ambient air. He weighed 65kgs. His skin
had3hypopigmentedandhypoaestheticpatchesontheright
chest wall and right upper arm. The largest lesion measured
5 by 6cm and the smallest 2 by 3cm. Other systems were
essentially normal. Baseline investigations revealed a CD4
cell count of 145/mL, CD4 percentage 10%, white blood cell
countof2800/uL,Hemoglobin12.3g/dL,andplateletscount
of 178,000/uL. SGPT and creatinine were within normal
ranges. His chest X-ray was without evidence of pathology.
An impression of Tinea corporis was made and the
patient assigned WHO clinical stage 2 due to weight loss of
<10%. He was given cotrimoxazole prophylactic therapy and
clotrimazole cream. One month later, the patient was started
on an ART regimen composed of stavudine, lamivudine,
and nevirapine after adherence counseling. The patient’s
progress (CD4 counts, viral load and weight) is summarized
in Table 1.
Thepatienthadpooradherencebaseduponmissedclinic
appointments and self report. There is documented history
that the patient did not take his medications for a period
of one month during the 3rd year of ART. He attributed
this to social stressors. An outreach worker had to visit his
home to remind him of clinic visits. After several adherence
counseling sessions, his plasma viral load dropped from
1,084,798/mL at 29 months of treatment to 433,376/mL six
months later. At this point, virological treatment failure was
c o n ﬁ r m e db a s e do nap l a s m av i r a ll o a do f>5000copies/mL.
A decision was made to continue with ﬁrst-line ART until
perfectadherenceismaintainedforatleastsixmonthsbefore
initiating second-line ART. All this time the skin lesions
persisted despite regular use of clotrimazole cream.
After demonstrating good adherence, the patient was
initiated on second-line ART regimen including abacavir,
didanosine, and aluvia (Lopinavir/Ritonavir) 47 months
after initiating ﬁrst-line ART. The skin lesions persisted but
did not increase in number or size. A decision to refer
him to the regional center for leprosy was made where a
skin smear was done and was positive for acid fast bacilli.
According to Ridley-Jopling system, he was classiﬁed as
having borderline tuberculoid leprosy based on having
three lesions only that were well demarcated, asymmetrical,
and unilateral. However, there was no enlargement of the
nerve trunks and no neurological deﬁcits other than the
hypoaesthesia. According to the WHO classiﬁcation, he was
classiﬁed as having multibacillary leprosy based on having
a positive skin smear on at least one site. Seven months
after initiating second-line ART, he was put on rifampicin
600mg monthly, clofazimine 300mg once a month and
50mg daily and dapsone 100mg daily for 12 months which
is the WHO recommended multidrug treatment (MDT)
regimen for multibacillary leprosy. Six months later, the skin
lesions had resolved, there was no neurological sequelea, and
a check viral load was 188copies/mL.
Eighteen months since initiating MDT for leprosy, the
patient remained stable without new lesions, nor neu-
rological deﬁcits. A follow-up skin biopsy showed mild
chronic inﬂammation with noncaseating granulomas. Fite’s
Acid fast stain for leprosy was negative. Genotypic viral
resistance testing performed revealed resistance mutations
to nonnucleotide reverse transcriptase inhibitors (NNRTI’s)
and nucleoside reverse transcriptase inhibitors (NRTI’s) but
none to protease inhibitors (PI’s).
3. Discussion:LeprosyinHIV-1 Disease
Globally, the new case detection rate of leprosy is generally
declining. The registered prevalence rate as of 2011 was
highest in the South East Asia (0.64/10,000 of the popu-
lation) followed by the African region (0.38/10,000 of the
population). In Africa, the highest number of new infections
in 2010 was reported in the Democratic Republic of Congo
followed by Ethiopia (5,049 and 4,430, resp.) [11]. In Kenya,
thenumberofnewleprosycasesdetecteddecreasedfrom630
in 1986 to 157 in 2009. Kenya is in the postelimination phase
of leprosy and thus HIV-1-leprosy coinfection is rare [12].
This is a case of M.leprae-HIV true coinfection according
to Talhari et al. classiﬁcation [13]. This classiﬁcation rec-
ognizes true leprosy-HIV-coinfection, opportunistic leprosy
disease, and leprosy related to ART. To the best of our
knowledge, this is the ﬁrst case of second-line ART in a
patient on treatment for leprosy reported in Kenya. This case
illustrates the challenges that face clinicians in the diagnosis
of leprosy in HIV-1-infected patients in low-resource setups.
In illustration, the diagnosis of leprosy was not thought of
for several years since his ﬁrst presentation to clinic. This
led to the patient being treated for a presumed fungal skin
infection for a long time before the deﬁnitive diagnosis was
made. We postulate that the rarity of leprosy in Kenya has led
toalowindexofsuspicionforthediseaseamongstclinicians.
Also, very few clinicians in Kenya have had clinical exposure
to leprosy. This means that few have the clinical experience
to recognize the lesions. In addition, a deﬁnitive diagnosis of
leprosy requires microscopic examination of skin specimens,
a tool that is not available in majority of facilities in Kenya.
The skin lesions of leprosy are classiﬁed morphologically
according to the Ridley-Jopling classiﬁcation system into
ﬁve groups based on the immunity [14]. Patients with a
strong immune system have tuberculoid leprosy in which
the skin lesions are usually hypopigmented, hypoaesthetic,
welldeﬁned with clear margins. They are usually asymmetric
and less than ﬁve in number. The nerve trunks tend to
enlarge and become palpable and may lead to signiﬁcant
neurological deformities. Patients with a poor immune
response develop lepromatous leprosy which is characterized
by numerous papules and nodules which are distributed
symmetrically. In between these poles is a spectrum that
includes borderline tuberculoid, borderline, and borderline
lepromatous in ascending order of severity. Presence of
hypopigmented hypoaesthetic skin lesions should prompt
the physician to consider a diagnosis of leprosy in a patient.
As noted earlier, HIV-1 does not seem to aﬀect the clini-
cal classiﬁcation and progression of leprosy. In a study by AS
Pereira et al. [15] the clinical, immunologic, histopathologic,
and virologic features among 22 HIV-1-leprosy-coinfected
Brazilian patients indicate that each disease progressed as
in single infection [15]. Despite overall HIV-associated
immunosuppression,cell-mediatedimmuneresponsestoM.Case Reports in Medicine 3
Table 1: Clinical, immunological, and virological parameters of an HIV-1-leprosy coinfected patient in western Kenya.
EVENT Weight (kg) CD4 count (Cells/mL) CD4% Plasma viral load (copies/mL)
Enrolment 65 145 10
ART initiated 1 month later
5m o n t h s ∗ 66 272 16
12 months∗ 64 154 13
15 months∗ 65 152 13
23 months∗ 62 192 11
27 months∗ 58 110 8
29 months∗ 1,084,798
32 months∗ 62 169 11
35 months ∗ 433,376
40 months∗ 60 155 13
45 months∗ 55 195 7
47 months: Switch to second-line ART
6m o n t h s ∗∗ 60 320 11
7m o n t h s ∗∗ Started antileprosy chemotherapy
13 months∗∗ 188
∗After ART initiation.
∗∗After initiation of second-line ART.
leprae are well preserved at the site of the disease [16]. In our
patient, the disease progressed slowly, and the lesions did not
alter morphologically over a period of 4 years of followup.
This suggests that the pathogenesis of leprosy in this patient
was unaﬀected by his HIV-1-related immunodeﬁciency.
The use of rifampicin in a patient on protease inhibitor-
based ART is problematic because of the potential for
drug interactions. Rifampicin is a potent inducer of the
cytochrome P450-3A4 subenzyme, which is responsible
for the metabolism of protease inhibitors (PI), amongst
other drugs [17, 18]. This may result in subtherapeutic
concentrations of the PI thus increasing the risk of treatment
failure and virological resistance. Studies have shown that
boostingaPIlikesaquinavirwithritonavir,astronginhibitor
of CYP3A4, may allow the coadministration of rifampicin.
However, the use of this regimen is limited by adverse events
due to higher doses of ritonavir (400mg) used for boosting.
This has been associated with increased hepatotoxicity,
nausea, and vomiting [19–22]. The most widely available
PI in Kenya and in most African countries is ritonavir-
boosted lopinavir. Coadministration of rifampicin with
standard dose lopinavir/ritonavir (400mg/100mg) leads
to a subtherapeutic concentration of the latter. However,
an adjusted dose of lopinavir/ritonavir (800mg/200mg
or 400mg/400mg) in combination with therapeutic drug
monitoring and monitoring of liver function may allow
concomitant use of rifampicin in healthy volunteers. How-
ever, this regimen is not well tolerated because of increased
incidence of nausea and vomiting [23].
In our patient, the treatment of leprosy required admin-
istration of rifampicin 600mg once a month. We presumed
that monthly rifampicin would have minimal interactions
with the lopinavir-/ritonavir-based ART. As such, we did not
adjust the dose of lopinavir/ritonavir in the realization that
such an adjustment would only serve to increase toxicity.
Thus the patient received standard dose lopinavir/ritonavir
together with monthly rifampicin. This combination was
well tolerated and resulted in good outcome for both
diseases. The skin lesions resolved within six months of
treatment and the viral load revealed good virological
control.
It is recommended that rifabutin should substitute
rifampicin in the treatment of TB in TB/HIV-1-coinfected
patients on PI-based ART [24, 25]. However, for the
treatment of leprosy, there is limited data to support the
use of rifabutin in HIV-1-leprosy-coinfected patients. Earlier
preclinical studies in mice and armadillos suggested that
rifabutin can be a substitute for rifampicin in the multidrug
treatment of leprosy [26, 27]. In addition, a number of in-
vitro studies have demonstrated the potency of rifabutin
against M.leprae [28–30]. However, there is a paucity of
data from clinical trials that evaluate the eﬃcacy of rifabutin
in the multidrug treatment of leprosy in HIV-1-coinfected
patients. Similarly, the substitution of rifampicin with a
ﬂoroquinolone in the multi-drug therapy for leprosy has not
been well tested in this population, if at all.
Ourmanagementofthispatientwasinformedbythefact
that there is no clinically validated substitute for rifampicin
in the treatment of leprosy in HIV-1-coinfected patients.
In addition to that, we did not have an alternative to
lopinavir/ritonavirforthetreatmentofHIV.Thoughwewere
unable to monitor the drug concentrations in his blood due
to resource limitation, surrogate markers such as the clinical,
immunological, and virological parameters suggested a good
response.
Initiation of ART has been associated with Immune Re-
constitution and Inﬂammatory Syndrome (IRIS) in various
situations. IRIS in leprosy may trigger potential adverse4 Case Reports in Medicine
eﬀects, such as leprosy acute inﬂammatory episodes [31–
34]. This usually leads to a worsening of the initial lesion
characterized by erythema and tenderness in the setting of
rising CD4 count and falling viral load. These reactions are
more common in patients with low CD4 counts especially
during the initial 3 months of initiation of ART. Typically,
as the immune system further recovers, the lesions become
tuberculoid/paucibacillary as opposed to lepromatous. In
our patient, there was no change in the appearance of the
skinlesionsafterstartingbothﬁrst-lineandsecond-lineART,
despite evident virological suppression and immune recon-
stitution with the latter. More so, there were no neurological
deﬁcits noted even after initiating potent second-line ART.
The follow-up skin biopsy revealed mild chronic der-
matitis, but Fite’s Acid fast stain was negative, suggesting that
the patient is cured of leprosy. The absence of PI resistance
mutations suggests that the dosing schedule of rifampicin
adopted in this patient did not adversely aﬀect the eﬃcacy
of the PI-based regimen. This, however, must be interpreted
with caution since it is known that PI’s have a high genetic
barrier to resistance.
4. Conclusion
Standard dose lopinavir-/ritonavir-based ART coadminis-
tered with monthly rifampicin may still achieve virological
suppression in HIV-1-leprosy coinfected patients.
Recommendations
More data are required to support our observation.
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